Similarly, the capacity for inhibition against clinically important enzymes involved in major pathologies, including neurological disorders (acetylcholinesterase, AChE; butyrylcholinesterase, BChE), skin conditions (tyrosinase), and diabetes (α-amylase), were also examined. This evidence concerns the gene BCHE and nervous system disorder.